165 related articles for article (PubMed ID: 37879236)
41. Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
Ma LX; Espin-Garcia O; Bedard PL; Stockley T; Prince R; Mete O; Krzyzanowska MK
Thyroid; 2022 Jun; 32(6):657-666. PubMed ID: 35262412
[No Abstract] [Full Text] [Related]
42. Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI).
Brose MS; Smit JWA; Lin CC; Tori M; Bowles DW; Worden F; Shen DH; Huang SM; Tsai HJ; Alevizaki M; Peeters RP; Takahashi S; Rumyantsev P; Guan R; Babajanyan S; Ozgurdal K; Sugitani I; Pitoia F; Lamartina L
Thyroid; 2022 Sep; 32(9):1059-1068. PubMed ID: 35950621
[No Abstract] [Full Text] [Related]
43. Racial Disparities in Differentiated Thyroid Cancer: Have We Bridged the Gap?
Shah SA; Adam MA; Thomas SM; Scheri RP; Stang MT; Sosa JA; Roman SA
Thyroid; 2017 Jun; 27(6):762-772. PubMed ID: 28294040
[TBL] [Abstract][Full Text] [Related]
44. Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population.
Li M; Jia H; Qian Q; Wen P; Chen C; Hua Y; Wang K; Zhang W; Shi F
Diagn Pathol; 2020 May; 15(1):49. PubMed ID: 32393293
[TBL] [Abstract][Full Text] [Related]
45. Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
Schechter RB; Nagilla M; Joseph L; Reddy P; Khattri A; Watson S; Locati LD; Licitra L; Greco A; Pelosi G; Carcangiu ML; Lingen MW; Seiwert TY; Cohen EE
Cancer Lett; 2015 Apr; 359(2):269-74. PubMed ID: 25641339
[TBL] [Abstract][Full Text] [Related]
46. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
47. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
[TBL] [Abstract][Full Text] [Related]
48. Radioactive iodine therapy strategies for distinct types of differentiated thyroid cancer: a propensity score-matched analysis.
Guo H; Zhang N; Hu Y; Zhang F; Huang T; Shen N
Front Endocrinol (Lausanne); 2023; 14():1158581. PubMed ID: 37664843
[TBL] [Abstract][Full Text] [Related]
49. Impact of Mutation Density and Heterogeneity on Papillary Thyroid Cancer Clinical Features and Remission Probability.
Colombo C; Muzza M; Proverbio MC; Tosi D; Soranna D; Pesenti C; Rossi S; Cirello V; De Leo S; Fusco N; Miozzo M; Bulfamante G; Vicentini L; Ferrero S; Zambon A; Tabano S; Fugazzola L
Thyroid; 2019 Feb; 29(2):237-251. PubMed ID: 30501571
[TBL] [Abstract][Full Text] [Related]
50. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review.
Anderson RT; Linnehan JE; Tongbram V; Keating K; Wirth LJ
Thyroid; 2013 Apr; 23(4):392-407. PubMed ID: 23294230
[TBL] [Abstract][Full Text] [Related]
51. Mutation profiles of follicular thyroid tumors by targeted sequencing.
Duan H; Liu X; Ren X; Zhang H; Wu H; Liang Z
Diagn Pathol; 2019 May; 14(1):39. PubMed ID: 31077238
[TBL] [Abstract][Full Text] [Related]
52. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.
Brose MS; Nutting CM; Sherman SI; Shong YK; Smit JW; Reike G; Chung J; Kalmus J; Kappeler C; Schlumberger M
BMC Cancer; 2011 Aug; 11():349. PubMed ID: 21834960
[TBL] [Abstract][Full Text] [Related]
53. Genetic Alterations in Pediatric Thyroid Cancer Using a Comprehensive Childhood Cancer Gene Panel.
Alzahrani AS; Alswailem M; Alswailem AA; Al-Hindi H; Goljan E; Alsudairy N; Abouelhoda M
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32556222
[TBL] [Abstract][Full Text] [Related]
54. TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower
Meng Z; Matsuse M; Saenko V; Yamashita S; Ren P; Zheng X; Jia Q; Tan J; Li N; Zheng W; Zhao L; Mitsutake N
IUBMB Life; 2019 Jul; 71(7):1030-1040. PubMed ID: 31026111
[TBL] [Abstract][Full Text] [Related]
55. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
56. Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan.
Toda S; Hiroshima Y; Iwasaki H; Masudo K
J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38630010
[TBL] [Abstract][Full Text] [Related]
57. Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival.
Jannin A; Lamartina L; Moutarde C; Djennaoui M; Lion G; Chevalier B; Vantyghem MC; Deschamps F; Hadoux J; Baudin E; Schlumberger M; Leboulleux S; Do Cao C
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2401-2413. PubMed ID: 35149914
[TBL] [Abstract][Full Text] [Related]
58. How do
Mukhtar N; Alhamoudi K; Alswailem M; Alhindi H; Murugan AK; Alghamdi B; Alzahrani AS
Front Endocrinol (Lausanne); 2023; 14():1270796. PubMed ID: 37859987
[TBL] [Abstract][Full Text] [Related]
59. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy.
Chen H; Luthra R; Routbort MJ; Patel KP; Cabanillas ME; Broaddus RR; Williams MD
Mol Cancer Ther; 2018 Jul; 17(7):1575-1584. PubMed ID: 29695638
[TBL] [Abstract][Full Text] [Related]
60. How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis.
Dell'Aquila M; Fiorentino V; Martini M; Capodimonti S; Cenci T; Lombardi CP; Raffaelli M; Pontecorvi A; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
Cancer Cytopathol; 2021 Oct; 129(10):819-829. PubMed ID: 34076961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
